Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation

Annals of Hematology

Volumn 89, Issue 2, 2010, Pages 141-146

  De Stefano, Valerio ^a   Za, Tommaso ^a   Rossi, Elena ^a   Vannucchi, Alessandro M ^b   Ruggeri, Marco ^c   Elli, Elena ^d   Micò, Caterina ^e   Tieghi, Alessia ^f   Cacciola, Rossella R ^g   Santoro, Cristina ^h   Vianelli, Nicola ⁱ   Guglielmelli, Paola ^b   Pieri, Lisa ^b   Scognamiglio, Francesca ^c   Cacciola, Emma ^g   Rodeghiero, Francesco ^c   Pogliani, Enrico M ^d   Finazzi, Guido ^e   Gugliotta, Luigi ^f   Leone, Giuseppe ^a   Barbui, Tiziano ^e   more..

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

^e OSPEDALI RIUNITI   (Italy)

^f S MARIA NUOVA HOSPITAL   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Essential thrombocythemia; JAK2 V617F mutation; Recurrent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BUSULFAN; HYDROXYUREA; INTERFERON; JANUS KINASE 2; PHENYLALANINE; PIPOBROMAN; TICLOPIDINE; VALINE;

ADULT; AGED; ALLELE; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTHEMIA; THROMBOSIS; VEIN THROMBOSIS; WILD TYPE; GENETICS; MIDDLE AGED; MUTATION; PATHOPHYSIOLOGY; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; RISK FACTORS; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS; YOUNG ADULT;

EID: 74049141807     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0788-5     Document Type: Article

References (19)

1. Elliott MA, Tefferi A (2005) Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128:275-290.
2. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8:556-562.
3. Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, Woessner S, Sans-Sabrafen J, Rozman C, Montserrat E (1999)Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 13:150-154.
4. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117:755-761.
5. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 81:159-166.
6. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delfini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood 109:2310-2313.
7. Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delfini F, Guerini V, Finazzi G, Rambaldi A, Barbui T (2008) Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 16:2732-2736.
8. Tefferi A, Gangat N, Wolanskyj A (2007) The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood 109:4105.
9. Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14-22.
10. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T (2007) Clinical prophile of homozygous JAK2V617F 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110:840-846.
11. Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M (2009) Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 33:67-73.
12. De Stefano V, Za T, Rossi E, Fiorini A, Ciminello A, Luzzi C, Chiusolo P, Sica S, Leone G (2009) Influence of the Jak2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica 94:733-737.
13. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S (2004) Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 89:215-232.
14. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Marchioli R, Leone G, Barbui T (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93:372-380.
15. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, ScottMA, ErberWN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061.
16. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945-1953.
17. Arellano-Rodrigo E, Alvarez-Larràn A, Reverter JC, Villamor N, Colomer D, Cervantes F (2006) Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91:169-175.
18. Marchetti M, Castaldi E, Spronk HM, van Oerle R, Calducci D, Barbui T, Rosing J, Ten Cate H, Falanga A (2008) Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 112:4061-4068.
19. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazi A, Ponziani V, Mogani C, Rossi Ferrini P, Rambaldi A, Guerini V, Bosi A, Barbui T (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2 V617F allele burden. Leukemia 21:1952-1959.